Review



sk mes 1 cells  (Procell Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Procell Inc sk mes 1 cells
    Functional impact of LATS2 upregulation on LUAD/LUSC cell viability and apoptosis. (A) Baseline LATS2 expression comparison in <t>A549</t> <t>(LUAD),</t> <t>SK-MES-1</t> (LUSC) and Beas-2B (normal bronchial) cell lines. (B) Western blot validation of LATS2 protein overexpression post-transfection. (C) Transfection efficiency confirmation via fluorescence labeling (MOI=10; transfection rate=90.5 and 90% in LUAD and LUSC, respectively). Scale bar, 100 µm. (D) qPCR quantification of LATS2 mRNA induction post-transfection. (E) MTT assay evaluation of cell proliferation changes following LATS2 upregulation. (F) Flow cytometry analysis of apoptosis rate alterations after LATS2 upregulation. Data are presented as mean ± SD and all comparisons were conducted using independent samples t-test. *P<0.05, **P<0.01 and ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BC, blank control; NC, negative control; OE, overexpression; OD, optical density; MOI, multiplicity of infection; qPCR, quantitative PCR.
    Sk Mes 1 Cells, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sk+mes+1+cells/pmc13247677-100-3-5?v=Procell+Inc
    Average 86 stars, based on 1 article reviews
    sk mes 1 cells - by Bioz Stars, 2026-06
    86/100 stars

    Images

    1) Product Images from "LATS2 expression differences in lung adenocarcinoma and lung squamous cell carcinoma analyzed using bioinformatics and experimental approaches"

    Article Title: LATS2 expression differences in lung adenocarcinoma and lung squamous cell carcinoma analyzed using bioinformatics and experimental approaches

    Journal: Oncology Letters

    doi: 10.3892/ol.2026.15671

    Functional impact of LATS2 upregulation on LUAD/LUSC cell viability and apoptosis. (A) Baseline LATS2 expression comparison in A549 (LUAD), SK-MES-1 (LUSC) and Beas-2B (normal bronchial) cell lines. (B) Western blot validation of LATS2 protein overexpression post-transfection. (C) Transfection efficiency confirmation via fluorescence labeling (MOI=10; transfection rate=90.5 and 90% in LUAD and LUSC, respectively). Scale bar, 100 µm. (D) qPCR quantification of LATS2 mRNA induction post-transfection. (E) MTT assay evaluation of cell proliferation changes following LATS2 upregulation. (F) Flow cytometry analysis of apoptosis rate alterations after LATS2 upregulation. Data are presented as mean ± SD and all comparisons were conducted using independent samples t-test. *P<0.05, **P<0.01 and ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BC, blank control; NC, negative control; OE, overexpression; OD, optical density; MOI, multiplicity of infection; qPCR, quantitative PCR.
    Figure Legend Snippet: Functional impact of LATS2 upregulation on LUAD/LUSC cell viability and apoptosis. (A) Baseline LATS2 expression comparison in A549 (LUAD), SK-MES-1 (LUSC) and Beas-2B (normal bronchial) cell lines. (B) Western blot validation of LATS2 protein overexpression post-transfection. (C) Transfection efficiency confirmation via fluorescence labeling (MOI=10; transfection rate=90.5 and 90% in LUAD and LUSC, respectively). Scale bar, 100 µm. (D) qPCR quantification of LATS2 mRNA induction post-transfection. (E) MTT assay evaluation of cell proliferation changes following LATS2 upregulation. (F) Flow cytometry analysis of apoptosis rate alterations after LATS2 upregulation. Data are presented as mean ± SD and all comparisons were conducted using independent samples t-test. *P<0.05, **P<0.01 and ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BC, blank control; NC, negative control; OE, overexpression; OD, optical density; MOI, multiplicity of infection; qPCR, quantitative PCR.

    Techniques Used: Functional Assay, Expressing, Comparison, Western Blot, Biomarker Discovery, Over Expression, Transfection, Fluorescence, Labeling, MTT Assay, Flow Cytometry, Control, Negative Control, Infection, Real-time Polymerase Chain Reaction

    Influence of LATS2 overexpression on LUAD and LUSC cell migration and invasion. (A) Wound healing assay in A549 cells. (B) Wound healing assay in SK-MES-1 cell lines. (C) Transwell assay evaluating altered invasive capacity of A549 and SK-MES-1 cells. (D) Comparison of cell migration rates. (E) Comparison of number of invading cells. Scale bar, 100 µm, **P<0.01 and ***P<0.001. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; LATS2, large tumor suppressor kinase 2; BC, blank control; NC, negative control; OE, overexpression.
    Figure Legend Snippet: Influence of LATS2 overexpression on LUAD and LUSC cell migration and invasion. (A) Wound healing assay in A549 cells. (B) Wound healing assay in SK-MES-1 cell lines. (C) Transwell assay evaluating altered invasive capacity of A549 and SK-MES-1 cells. (D) Comparison of cell migration rates. (E) Comparison of number of invading cells. Scale bar, 100 µm, **P<0.01 and ***P<0.001. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; LATS2, large tumor suppressor kinase 2; BC, blank control; NC, negative control; OE, overexpression.

    Techniques Used: Over Expression, Migration, Wound Healing Assay, Transwell Assay, Comparison, Control, Negative Control



    Similar Products

    human nsclc cell lines  (ATCC)
    96
    ATCC human nsclc cell lines
    Human Nsclc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sk+mes+1+cells/pm42029771-45-0-24?v=ATCC
    Average 96 stars, based on 1 article reviews
    human nsclc cell lines - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    sk mes 1 cells  (Procell Inc)
    86
    Procell Inc sk mes 1 cells
    Functional impact of LATS2 upregulation on LUAD/LUSC cell viability and apoptosis. (A) Baseline LATS2 expression comparison in <t>A549</t> <t>(LUAD),</t> <t>SK-MES-1</t> (LUSC) and Beas-2B (normal bronchial) cell lines. (B) Western blot validation of LATS2 protein overexpression post-transfection. (C) Transfection efficiency confirmation via fluorescence labeling (MOI=10; transfection rate=90.5 and 90% in LUAD and LUSC, respectively). Scale bar, 100 µm. (D) qPCR quantification of LATS2 mRNA induction post-transfection. (E) MTT assay evaluation of cell proliferation changes following LATS2 upregulation. (F) Flow cytometry analysis of apoptosis rate alterations after LATS2 upregulation. Data are presented as mean ± SD and all comparisons were conducted using independent samples t-test. *P<0.05, **P<0.01 and ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BC, blank control; NC, negative control; OE, overexpression; OD, optical density; MOI, multiplicity of infection; qPCR, quantitative PCR.
    Sk Mes 1 Cells, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sk+mes+1+cells/pmc13247677-100-3-5?v=Procell+Inc
    Average 86 stars, based on 1 article reviews
    sk mes 1 cells - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    sk mes 1 cells cl 0213  (Procell Inc)
    86
    Procell Inc sk mes 1 cells cl 0213
    Functional impact of LATS2 upregulation on LUAD/LUSC cell viability and apoptosis. (A) Baseline LATS2 expression comparison in <t>A549</t> <t>(LUAD),</t> <t>SK-MES-1</t> (LUSC) and Beas-2B (normal bronchial) cell lines. (B) Western blot validation of LATS2 protein overexpression post-transfection. (C) Transfection efficiency confirmation via fluorescence labeling (MOI=10; transfection rate=90.5 and 90% in LUAD and LUSC, respectively). Scale bar, 100 µm. (D) qPCR quantification of LATS2 mRNA induction post-transfection. (E) MTT assay evaluation of cell proliferation changes following LATS2 upregulation. (F) Flow cytometry analysis of apoptosis rate alterations after LATS2 upregulation. Data are presented as mean ± SD and all comparisons were conducted using independent samples t-test. *P<0.05, **P<0.01 and ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BC, blank control; NC, negative control; OE, overexpression; OD, optical density; MOI, multiplicity of infection; qPCR, quantitative PCR.
    Sk Mes 1 Cells Cl 0213, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sk+mes+1+cells/pm41787591-68-9-16?v=Procell+Inc
    Average 86 stars, based on 1 article reviews
    sk mes 1 cells cl 0213 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    nsclc cell lines  (ATCC)
    96
    ATCC nsclc cell lines
    Functional impact of LATS2 upregulation on LUAD/LUSC cell viability and apoptosis. (A) Baseline LATS2 expression comparison in <t>A549</t> <t>(LUAD),</t> <t>SK-MES-1</t> (LUSC) and Beas-2B (normal bronchial) cell lines. (B) Western blot validation of LATS2 protein overexpression post-transfection. (C) Transfection efficiency confirmation via fluorescence labeling (MOI=10; transfection rate=90.5 and 90% in LUAD and LUSC, respectively). Scale bar, 100 µm. (D) qPCR quantification of LATS2 mRNA induction post-transfection. (E) MTT assay evaluation of cell proliferation changes following LATS2 upregulation. (F) Flow cytometry analysis of apoptosis rate alterations after LATS2 upregulation. Data are presented as mean ± SD and all comparisons were conducted using independent samples t-test. *P<0.05, **P<0.01 and ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BC, blank control; NC, negative control; OE, overexpression; OD, optical density; MOI, multiplicity of infection; qPCR, quantitative PCR.
    Nsclc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sk+mes+1+cells/pm41267551-55-9-22?v=ATCC
    Average 96 stars, based on 1 article reviews
    nsclc cell lines - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    human lung squamous cell carcinoma cells  (ATCC)
    96
    ATCC human lung squamous cell carcinoma cells
    Functional impact of LATS2 upregulation on LUAD/LUSC cell viability and apoptosis. (A) Baseline LATS2 expression comparison in <t>A549</t> <t>(LUAD),</t> <t>SK-MES-1</t> (LUSC) and Beas-2B (normal bronchial) cell lines. (B) Western blot validation of LATS2 protein overexpression post-transfection. (C) Transfection efficiency confirmation via fluorescence labeling (MOI=10; transfection rate=90.5 and 90% in LUAD and LUSC, respectively). Scale bar, 100 µm. (D) qPCR quantification of LATS2 mRNA induction post-transfection. (E) MTT assay evaluation of cell proliferation changes following LATS2 upregulation. (F) Flow cytometry analysis of apoptosis rate alterations after LATS2 upregulation. Data are presented as mean ± SD and all comparisons were conducted using independent samples t-test. *P<0.05, **P<0.01 and ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BC, blank control; NC, negative control; OE, overexpression; OD, optical density; MOI, multiplicity of infection; qPCR, quantitative PCR.
    Human Lung Squamous Cell Carcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sk+mes+1+cells/pm41173824-227-0-7?v=ATCC
    Average 96 stars, based on 1 article reviews
    human lung squamous cell carcinoma cells - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    squamous cell carcinoma cell lines  (ATCC)
    96
    ATCC squamous cell carcinoma cell lines
    Functional impact of LATS2 upregulation on LUAD/LUSC cell viability and apoptosis. (A) Baseline LATS2 expression comparison in <t>A549</t> <t>(LUAD),</t> <t>SK-MES-1</t> (LUSC) and Beas-2B (normal bronchial) cell lines. (B) Western blot validation of LATS2 protein overexpression post-transfection. (C) Transfection efficiency confirmation via fluorescence labeling (MOI=10; transfection rate=90.5 and 90% in LUAD and LUSC, respectively). Scale bar, 100 µm. (D) qPCR quantification of LATS2 mRNA induction post-transfection. (E) MTT assay evaluation of cell proliferation changes following LATS2 upregulation. (F) Flow cytometry analysis of apoptosis rate alterations after LATS2 upregulation. Data are presented as mean ± SD and all comparisons were conducted using independent samples t-test. *P<0.05, **P<0.01 and ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BC, blank control; NC, negative control; OE, overexpression; OD, optical density; MOI, multiplicity of infection; qPCR, quantitative PCR.
    Squamous Cell Carcinoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sk+mes+1+cells/10__1097_slash_md__0000000000045095-63-12-24?v=ATCC
    Average 96 stars, based on 1 article reviews
    squamous cell carcinoma cell lines - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    human lusc cell lines sk mes 1  (ATCC)
    96
    ATCC human lusc cell lines sk mes 1
    Functional impact of LATS2 upregulation on LUAD/LUSC cell viability and apoptosis. (A) Baseline LATS2 expression comparison in <t>A549</t> <t>(LUAD),</t> <t>SK-MES-1</t> (LUSC) and Beas-2B (normal bronchial) cell lines. (B) Western blot validation of LATS2 protein overexpression post-transfection. (C) Transfection efficiency confirmation via fluorescence labeling (MOI=10; transfection rate=90.5 and 90% in LUAD and LUSC, respectively). Scale bar, 100 µm. (D) qPCR quantification of LATS2 mRNA induction post-transfection. (E) MTT assay evaluation of cell proliferation changes following LATS2 upregulation. (F) Flow cytometry analysis of apoptosis rate alterations after LATS2 upregulation. Data are presented as mean ± SD and all comparisons were conducted using independent samples t-test. *P<0.05, **P<0.01 and ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BC, blank control; NC, negative control; OE, overexpression; OD, optical density; MOI, multiplicity of infection; qPCR, quantitative PCR.
    Human Lusc Cell Lines Sk Mes 1, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sk+mes+1+cells/pm40752594-59-16-26?v=ATCC
    Average 96 stars, based on 1 article reviews
    human lusc cell lines sk mes 1 - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Functional impact of LATS2 upregulation on LUAD/LUSC cell viability and apoptosis. (A) Baseline LATS2 expression comparison in A549 (LUAD), SK-MES-1 (LUSC) and Beas-2B (normal bronchial) cell lines. (B) Western blot validation of LATS2 protein overexpression post-transfection. (C) Transfection efficiency confirmation via fluorescence labeling (MOI=10; transfection rate=90.5 and 90% in LUAD and LUSC, respectively). Scale bar, 100 µm. (D) qPCR quantification of LATS2 mRNA induction post-transfection. (E) MTT assay evaluation of cell proliferation changes following LATS2 upregulation. (F) Flow cytometry analysis of apoptosis rate alterations after LATS2 upregulation. Data are presented as mean ± SD and all comparisons were conducted using independent samples t-test. *P<0.05, **P<0.01 and ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BC, blank control; NC, negative control; OE, overexpression; OD, optical density; MOI, multiplicity of infection; qPCR, quantitative PCR.

    Journal: Oncology Letters

    Article Title: LATS2 expression differences in lung adenocarcinoma and lung squamous cell carcinoma analyzed using bioinformatics and experimental approaches

    doi: 10.3892/ol.2026.15671

    Figure Lengend Snippet: Functional impact of LATS2 upregulation on LUAD/LUSC cell viability and apoptosis. (A) Baseline LATS2 expression comparison in A549 (LUAD), SK-MES-1 (LUSC) and Beas-2B (normal bronchial) cell lines. (B) Western blot validation of LATS2 protein overexpression post-transfection. (C) Transfection efficiency confirmation via fluorescence labeling (MOI=10; transfection rate=90.5 and 90% in LUAD and LUSC, respectively). Scale bar, 100 µm. (D) qPCR quantification of LATS2 mRNA induction post-transfection. (E) MTT assay evaluation of cell proliferation changes following LATS2 upregulation. (F) Flow cytometry analysis of apoptosis rate alterations after LATS2 upregulation. Data are presented as mean ± SD and all comparisons were conducted using independent samples t-test. *P<0.05, **P<0.01 and ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BC, blank control; NC, negative control; OE, overexpression; OD, optical density; MOI, multiplicity of infection; qPCR, quantitative PCR.

    Article Snippet: The A549 and SK-MES-1 cells (Procell Life Science & Technology Co., Ltd.) were divided into BC (blank control (BC), negative control (NC) and overexpression (OE) groups.

    Techniques: Functional Assay, Expressing, Comparison, Western Blot, Biomarker Discovery, Over Expression, Transfection, Fluorescence, Labeling, MTT Assay, Flow Cytometry, Control, Negative Control, Infection, Real-time Polymerase Chain Reaction

    Influence of LATS2 overexpression on LUAD and LUSC cell migration and invasion. (A) Wound healing assay in A549 cells. (B) Wound healing assay in SK-MES-1 cell lines. (C) Transwell assay evaluating altered invasive capacity of A549 and SK-MES-1 cells. (D) Comparison of cell migration rates. (E) Comparison of number of invading cells. Scale bar, 100 µm, **P<0.01 and ***P<0.001. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; LATS2, large tumor suppressor kinase 2; BC, blank control; NC, negative control; OE, overexpression.

    Journal: Oncology Letters

    Article Title: LATS2 expression differences in lung adenocarcinoma and lung squamous cell carcinoma analyzed using bioinformatics and experimental approaches

    doi: 10.3892/ol.2026.15671

    Figure Lengend Snippet: Influence of LATS2 overexpression on LUAD and LUSC cell migration and invasion. (A) Wound healing assay in A549 cells. (B) Wound healing assay in SK-MES-1 cell lines. (C) Transwell assay evaluating altered invasive capacity of A549 and SK-MES-1 cells. (D) Comparison of cell migration rates. (E) Comparison of number of invading cells. Scale bar, 100 µm, **P<0.01 and ***P<0.001. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; LATS2, large tumor suppressor kinase 2; BC, blank control; NC, negative control; OE, overexpression.

    Article Snippet: The A549 and SK-MES-1 cells (Procell Life Science & Technology Co., Ltd.) were divided into BC (blank control (BC), negative control (NC) and overexpression (OE) groups.

    Techniques: Over Expression, Migration, Wound Healing Assay, Transwell Assay, Comparison, Control, Negative Control